Rare Diseases - Market Size

Part
01
of eight
Part
01

Idiopathic Thrombocytopenic Purpura (ITP) - US Prevalence

The adjusted incidence rate of Idiopathic Thrombocytopenic Purpura (ITP) is 0.0095% of the total population and the number of people with ITP in the U.S. are 31,065 people. Below is an overview of the findings.

KEY FINDINGS

  • "The incidence of ITP in adults is approximately 66 cases per 1,000,000 per year."
  • The number of adults in the U.S. diagnosed each year (incidence) with immune thrombocytopenia is estimated to be 3.3 per 100,000 adults.
  • Among adults in the U.S. between the ages of 30-60 years diagnosed with chronic ITP, there are 2.6 cases among women for every case involving a male. For older adults, the number of men and women diagnosed are almost equal with 52% male to 48% female.
  • There are 9.5 cases of adults with ITP per 100,000 at any time (prevalence).
  • Among children, this is estimated to be 5.3 per 100,000. The number of children with ITP is usually equal to the number of children diagnosed with ITP annually because children with ITP usually recover from it.
  • Each year in the U.S., of the children under the age of 15 years, between four to eight children per 100,000 children are affected by ITP.
  • Children younger than 10 years make up 40% of all patients diagnosed with some form of ITP.
  • "The age-adjusted prevalence of immune thrombocytopenic purpura (ITP) is estimated to be 9.5 per 100,000 persons" in the US.
  • The number of people with ITP is estimated to be 31,065 and the estimated incidence rate is 0.0095%. (see calculations below)

U.S. Population According to the US Census Bureau

  • The U.S. has an estimated population of 327,167,434 people as of July 2018.

RESEARCH STRATEGY

We were able to find some statistics for the incidence rate of Idiopathic Thrombocytopenic Purpura (ITP) in the U.S., most of the statistics provided were either for adults or children with a specific age range.

Please note that the finding "The age-adjusted prevalence of immune thrombocytopenic purpura (ITP) is estimated to be 9.5 per 100,000 persons in the US" comes from a dated source, however, there is no more recent data publicly available that contravenes this.

CALCULATIONS
U.S. population in 2018 = 327,167,434 people
Prevalence of ITP = 9.5 person per 100,000 = 9.5*10=95 people per million
Number of people with ITP = (327 million/1 million) x 95 = 31,065 people
Converting to Percentage=[31,065/327,000,000]*100=0.0095%
Hence, 0.0095% of Americans have ITP and the adjusted incidence rate of ITP is 0.0095% of the total population and the people with ITP in the U.S. are 31,065 people.

Part
02
of eight
Part
02

Idiopathic Thrombocytopenic Purpura (ITP) - Global Prevalence

The number of adults with Idiopathic Thrombocytopenic Purpura, (ITP) is approximately 620,928 adults. The number of children with ITP is averagely 1,117,500 children giving a sum of 1,738,428 people with the illness worldwide. There are 3.3 adults in every 100,000 diagnosed with the illness yearly.

GLOBAL PREVALENCE OF ITP


RESEARCH STRATEGY:

To determine the prevalence and incidence rate of ITP globally, the research team searched scientific and medical databases for the latest publications or articles containing statistical data regarding ITP. However, most of the sources found are publications that are more than two years old. We broadened the search to other medical reports and were able to find information on the number of adults diagnosed yearly and adults already living with the illness worldwide. Unfortunately, we were not able to find any information on the number of adolescents with the illness. This may be because cases are more prevalent in adults and children, as opposed to adolescents/teenagers.

For the purposes of our triangulation, we adopted the United Nations definition of an adult, which is someone that is at least 19 years old. We also used data from UNICEF to determine the number of adolescents in the world population.

Finally, we used pre-existing information on the global population to enable our triangulation.

CALCULATIONS

Using 2018 population statistics:
World population ≈ 7.621 billion people
Number of Adolescents (10 – 19) years ≈ 1.2 billion
Number of people below the age of 15 ≈ 149 million
Neglecting the ages between 10 – 14 years (since their number is relatively negligible compared to the world population)

Based on these populations, we determined that there are 620,928 adults with ITP, 1,117,500 children with ITP, and a total of 1,738,428 people in the world with ITP.
Number of adults in the world = 7.621 — (1.2 + 0.149) ≈ 6.272 billion
ratio of adults with ITP = 9.9 adults in every 100,000
6.272 billion / 100,000 = 62,720
Number of adults with ITP = 9.9 * 62,720 = 620,928 adults.

Number of children with the illness is 0.5-1%, taking the average = 0.75%
0.75 * 149 million = 1,117,500 children

Total estimate of the world population with Idiopathic Thrombocytopenic Purpura = 1,117,500 + 620,928 = 1,738,428 people.
Part
03
of eight
Part
03

Myasthenia Gravis - US Prevalence

There are about 60,000 people suffering from Myasthenia Gravis in the United States and it has a prevalence rate of approximately 0.02%.

MYASTHENIA GRAVIS

  • According to the population studies done for a period of over 50 years, there has been an increasing trend in the prevalence of the disease.
  • There are approximately 60, 000 patients suffering from Myasthenia Gravis.
  • Prevalence rate is 0.02%
  • Incidence rate for black women is 0.001% /year.
  • Incidence rate for white women 0.0009% / year.
  • Incidence rate for white men is 0.0008% /year.
  • Incidence rate for black men is 0.0007% /year.

RESEARCH STRATEGY

We commenced our research by looking into medical articles and government reports. We found credible detailed reports on Myasthenia Gravis. We only used the latest credible data found.
Part
04
of eight
Part
04

Myasthenia Gravis - Global Prevalence

More than 700,000 people all over the world are suffering from Myasthenia gravis. The annual global incidence of Myasthenia gravis is approximately 0.0004% to 0.0012%, and the global prevalence rate is estimated to be at 0.0015% to 0.025%.

MYASTHENIA GRAVIS: GLOBAL PREVALENCE & INCIDENCE RATE

  • There are more than 700,000 people all over the world suffering from Myasthenia gravis (MG).
  • Studies show that the annual global incidence of MG is estimated to be 4 to 12 per million, and the prevalence rate ranges from 15 to 250 per million.
  • According to research, the total prevalent population of MG in the seven major markets was found to be 129,267 in 2016.
  • Worldwide prevalence of MG is 7.8 cases per 100,000 people.
  • The prevalence of MG is higher in females, which is often seen in autoimmune conditions. The female to male ratio commonly is set at 3:1, and ratios as high as 9:1 have occasionally been reported. However, the gender ratio in late-onset MG (LOMG) shows a slight male predominance.

RESEARCH STRATEGY

We commenced our research by looking into medical reports, articles, studies, and journals. We found credible reports on Myasthenia gravis from trusted sources, like IntechOpen, Terumo BCT, and Uppsala University Publications. We used the latest credible data we found and presented the information in percentage form to directly answer the client. Below is our computation in converting the data into percentages:

GIVEN:
The annual global incidence of MG is estimated to be 4 to 12 per million, and the prevalence rate ranges from 15 to 250 per million.

Global Incidence: 4 to 12 per million
  • (4/1million) X 100% to (12/1million) X 100%
  • 0.0004% to 0.0012%

Global Prevalence : 15 to 250 per million
  • (15/1million) X 100% to (250/1million) X 100%
  • 0.0015% to 0.025%
In conclusion, the annual global incidence of MG is approximately 0.0004% to 0.0012%, and the global prevalence rate is estimated to be 0.0015% to 0.025%.

Part
05
of eight
Part
05

Idiopathic Thrombocytopenic Purpura (ITP) - US Market Size

The triangulated market size of Idiopathic Thromboctopenic Purpura (ITP) treatment in the Americas market, consisting of the US, Canada and Latin America, was valued at $486.2 million in 2018. Also, the global market for the ITP treatment was valued at $1670.9 million in 2017. Leading US companies in ITP treatment include Rigel Pharmaceuticals, Dova Pharmaceuticals, and Ligand Pharmaceuticals.

ITP US MARKET SIZE

  • The triangulated market size of ITP treatment in the Americas, consisting of the US, Canada and Latin America, in 2018 is $486.2 million. The triangulation details can be found in the research strategy section.

OTHER HELPFUL FINDINGS

  • The global market for the ITP treatment was valued at $1670.9 million in 2017. Moreover, the ITP global market size is set to reach $2361.2 million by 2023. The Americas accounted for 43.3% of the global market size in 2017, and the ITP treatment market size is expected to grow at a CAGR of 5.78% annually from 2018 till 2023.
  • The market size of ITP treatment is expected to grow over $265.7 million between 2019 and 2023. 43% of the growth will be in the Americas, and leading US companies in ITP treatment are Rigel Pharmaceuticals, Amgen Inc., Dova Pharmaceuticals and Ligand Pharmaceuticals.

RESEARCH STRATEGY:

From the information obtained in the original sources such as Market Research Future and Technavio, we were able to triangulate the 2018 market size of the Americas. The global market size of the ITP treatment was $1069.8 million in 2017. The CAGR projected for 2018-2023 is set at 5.78%. We were able to calculate the global market size for 2018 using the reverse CAGR calculator which is $1130.79 million.
To get the Americas market size, we used the calculated 2018 market size of $1130.79 million with the expected percentage of growth based projected growth of the Americas at 43% from 2018-2023. Using this information, the Americas market share in 2018 is 1130.79/43% = $486.2 million.

To find information on the US ITP treatment and market size, our first strategy was to search through various general and pharmaceutical databases that could contain information on ITP. We searched through databases such as American Factfinder, the FDA orange book website and Drug bank. However, we were unable to find anything in reference to ITP treatment drugs.
Our second strategy was to research various treatments used to treat the disease in the United States and links to various pharmaceutical companies, and then look through their annual reports. Although we were able to find a list of all drugs for ITP on drugs.com, the list contained so many drugs that were not labeled by the brand name that it would have taken over five hours to research all of the drugs.
We therefore decided to triangulate the information. After searching various market reports and business news websites on market size information for ITP, we were able to access reports from sites such as Marketwatch, Businesswire and Market Research Publisher. Most of the websites linked to the same source, and so we were able to access the summary of the information from the source, regarless of it being paywalled. However, all the sources had information on the global and regional market size for future or past years, but not specifically for the United States. On closer examination, we realized that no other major pharmaceutical company mentioned in the source came from any other parts of the Americas, other than the US. We therefore expanded the research criteria to include the Americas.
Part
06
of eight
Part
06

Idiopathic Thrombocytopenic Purpura (ITP) - Global Market Size

The current Idiopathic Thrombocytopenic Purpura global market size is $1,869,638,249.

Market Size

Market Trends

Biosimilars Becoming Popular

  • Biosimilars are about 20% less expensive to produce than biologics. This has made them an attractive proposition.
  • A senior research analyst at Technavio stated that The development of biosimilars has created a favorable environment for new vendors to enter the market. Thus, the positive response toward biosimilars will drive the immune thrombocytopenia drugs market in terms of volume during the forecast period".
  • Biosimilars are defined as: "A biosimilar medicine (also sometimes known as a “follow-on biologic,” “subsequent-entry biologic” or “follow-on protein product”) is a medicine that is similar to another, already-authorized biologic medicine (including vaccines, blood and blood components, allergenics, somatic cells, gene therapies, tissues and recombinant therapeutic proteins)."

The Largest Markets

  • After North America, the largest Idiopathic Thrombocytopenic Purpura markets are "Europe, Asia, and ROW respectively". The fastest growing market other than North America is Asia-Pacific, which is expected to have a CAGR of 4.40% from 2018 to 2023.

Research Strategy:

While most of the information was readily available, it was necessary to triangulate the exact current 2019 market value. A report found at amarketresearchgazette, indicated that the "market was valued at $1,670.9 million in 2017". The market CAGR for 2018 to 2023 is 5.78%.

Using this information and the CAGR Calculator, we calculated that the 2019 market is worth $1,869,638,249.
Part
07
of eight
Part
07

Myasthenia Gravis - US Market Size

The market size of the U.S. for Myasthenia Gravis treatments was triangulated using the U.S. population affected by the disease and determined to be between $31.87 million and $91.14 million in 2018 and $83.37 million and $197.77 million in 2025. The market size of the U.S. for Myasthenia Gravis treatments was triangulated using the percentage of the key companies. It is determined to be between $661.55 million and $925.24 million in 2025 and $304.88 million and $426.4 million in 2018.

Global Market Research

Myasthenia Gravis Rates

Trends

Research Strategy

The information for the Myasthenia Gravis (MG) market specific to the U.S. could not be found, so we decided to triangulate the U.S. market size from the global market size using the rate of prevalence of MG in the U.S. and globally.

Triangulation 1: People affected by MG
Triangulation 2: ratio of U.S. to globally affected people
  • 46,074/1,540,000 = 0.0299
  • 131,640/1,540,000 = 0.0855

Triangulation 3: The U.S. market using ratio of U.S. population with MG to global population
Triangulation 4: percent of U.S. companies as key players
Triangulation 5: The U.S. market using percent of U.S. companies as key players

Part
08
of eight
Part
08

Myasthenia Gravis - Global Market Size

The current global market size for Myasthenia Gravis is valued at $1,066 million USD in 2018.

KEY FINDINGS

Sources
Sources

From Part 04
Quotes
  • "The annual global incidence of MG is estimated to be 4–12 per million and the prevalence rate ranges from 15 to 250 per million. As older epidemiological MG studies tend to report lower prevalence rates than more recent surveys, the wide prevalence range is probably explained by modified research methodology over time, as well as novel disease knowledge, improved treatment regimens and an increased number of elderly people in the population"
From Part 06
Quotes
  • "The global immune thrombocytopenia (ITP) market was valued at USD 1,670.9 million in 2017 and is expected to register a CAGR of 5.78% during the forecast period from 2018 to 2023."
Quotes
  • "Global Immune Thrombocytopenia (ITP) Market is projected to grow at blooming CAGR of around 5.78% over the forecast period and market size will reach worth around 2361.2 Million US$ in 2018-2023."
Quotes
  • "The global immune thrombocytopenia (ITP) market has been segmented, by type, treatment, and end user."
Quotes
  • "“The development of biosimilars has created a favorable environment for new vendor to enter the market. Thus, the positive response toward biosimilars will drive the immune thrombocytopenia drugs market in terms of volume during the forecast period,” says a senior research analyst at Technavio."
Quotes
  • "A biosimilar medicine (also sometimes known as a “follow-on biologic,” “subsequent-entry biologic” or “follow-on protein product”) is a medicine that is similar to another, already-authorized biologic medicine (including vaccines, blood and blood components, allergenics, somatic cells, gene therapies, tissues and recombinant therapeutic proteins)."
From Part 08
Quotes
  • "According to the report, the global myasthenia gravis market was valued at approximately USD 1,066 million in 2018 and is expected to generate around USD 2,091 million by 2025, at a CAGR of around 10.2% between 2019 and 2025."
Quotes
  • "The global myasthenia gravis market has been segmented on the basis of its type, diagnosis and treatment, end-user and regional demand. "
Quotes
  • "The competition in the global myasthenia gravis market seems to be quite tough. Several players account for small shares in market."
Quotes
  • "The rise in geriatric population contributes significantly to the growth of this market as the person above 60 is more prone to such diseases. The government approval for use of monoclonal antibodies for treatment is yet another contributing factor in the growth of the market. "
Quotes
  • "This report focuses on the global Myasthenia Gravis status, future forecast, growth opportunity, key market and key players. "
Quotes
  • "the report depicts various myasthenia gravis drugs market growth influential factors which comprise raw material sources, industry environment, rapidly increasing demand, and technological developments. "